68 related articles for article (PubMed ID: 34422634)
1. Combining Clinicopathological Parameters and Molecular Indicators to Predict Lymph Node Metastasis in Endometrioid Type Endometrial Adenocarcinoma.
Jiang P; Huang Y; Tu Y; Li N; Kong W; Di F; Jiang S; Zhang J; Yi Q; Yuan R
Front Oncol; 2021; 11():682925. PubMed ID: 34422634
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for pelvic and para-aortic lymph node metastasis in non-endometrioid endometrial cancer.
Sun Y; Wang Y; Cheng X; Wu W; Liu Q; Chen X; Ren F
Eur J Surg Oncol; 2024 Apr; 50(4):108260. PubMed ID: 38484492
[TBL] [Abstract][Full Text] [Related]
3. A postoperative tumor-specific death prediction model for patients with endometrial cancer: a retrospective study.
Chen H; Yan W; Xu D; Wang Q; Yu Y; Huang J; Zhou Q; Xiao W; Lukanovic D; Barra F; Izzotti A; Jiang F
Transl Cancer Res; 2024 Feb; 13(2):1083-1090. PubMed ID: 38482453
[TBL] [Abstract][Full Text] [Related]
4. Systemic Immune-Inflammatory Index as a Predictor of Lymph Node Metastasis in Endometrial Cancer.
Lei H; Xu S; Mao X; Chen X; Chen Y; Sun X; Sun P
J Inflamm Res; 2021; 14():7131-7142. PubMed ID: 34992410
[TBL] [Abstract][Full Text] [Related]
5. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
6. RE: Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Nahshon C; Lavie O
J Natl Cancer Inst; 2022 Feb; 114(2):320-321. PubMed ID: 34424329
[No Abstract] [Full Text] [Related]
7. Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers.
Ni Y; Soliman A; Joehlin-Price A; Abdul-Karim F; Rose PG; Mahdi H
Immunotherapy; 2021 Oct; 13(14):1179-1192. PubMed ID: 34424031
[TBL] [Abstract][Full Text] [Related]
8. Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
Baiden-Amissah REM; Annibali D; Tuyaerts S; Amant F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439142
[TBL] [Abstract][Full Text] [Related]
9.
Kaneko E; Sato N; Sugawara T; Noto A; Takahashi K; Makino K; Terada Y
J Gynecol Oncol; 2021 Nov; 32(6):e79. PubMed ID: 34431253
[TBL] [Abstract][Full Text] [Related]
10. Is obesity predictive of endometrial cancer for women with postmenopausal bleeding?
Goodman A
Menopause; 2021 Aug; 28(10):1081-1082. PubMed ID: 34429390
[No Abstract] [Full Text] [Related]
11. [A nomogram for predicting lymph node metastasis in early gastric cancer].
Cui H; Cao B; Deng H; Liu GB; Liang WQ; Xie TY; Ye L; Zhang QP; Wang N; Liu FD; Wei B
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):40-47. PubMed ID: 35067033
[No Abstract] [Full Text] [Related]
12. The prognostic value of co-expression of stemness markers CD44 and CD133 in endometrial cancer.
Jiang P; Tian C; Zheng Y; Gong C; Wang J; Liu Y
Front Oncol; 2024; 14():1338908. PubMed ID: 38706601
[TBL] [Abstract][Full Text] [Related]
13. The value of machine learning in preoperative identification of lymph node metastasis status in endometrial cancer: a systematic review and meta-analysis.
Ren Z; Chen B; Hong C; Yuan J; Deng J; Chen Y; Ye J; Li Y
Front Oncol; 2023; 13():1289050. PubMed ID: 38173835
[TBL] [Abstract][Full Text] [Related]
14. YAP1 affects the prognosis through the regulation of stemness in endometrial cancer.
Kong W; Huang Y; Jiang P; Tu Y; Li N; Wang J; Zhou Q; Zheng Y; Gou S; Tian C; Yuan R
PeerJ; 2023; 11():e15891. PubMed ID: 37744228
[TBL] [Abstract][Full Text] [Related]
15. Systemic analysis of the expression and prognostic significance of USP31 in endometrial cancer.
Huang Y; Jiang P; Chen Y; Wang J; Yuan R
Biomol Biomed; 2023 May; 23(3):426-436. PubMed ID: 36508192
[TBL] [Abstract][Full Text] [Related]
16. Predicting the Recurrence of Operable Cervical Cancer Patients Based on Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Classical Clinicopathological Parameters.
Jiang P; Kong W; Gong C; Chen Y; Li F; Xu L; Yang Y; Gou S; Hu Z
J Inflamm Res; 2022; 15():5265-5281. PubMed ID: 36120183
[TBL] [Abstract][Full Text] [Related]
17. External validation study of endometrial cancer preoperative risk stratification model (ENDORISK).
Vinklerová P; Ovesná P; Hausnerová J; Pijnenborg JMA; Lucas PJF; Reijnen C; Vrede S; Weinberger V
Front Oncol; 2022; 12():939226. PubMed ID: 35992828
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy in high-risk endometrial cancer: performance, outcomes, and future avenues.
Kim YN; Kim YT
Obstet Gynecol Sci; 2022 Sep; 65(5):395-405. PubMed ID: 35916013
[TBL] [Abstract][Full Text] [Related]
19. A Model to Identify Candidates for Lymph Node Dissection Among Patients With High-Risk Endometrial Endometrioid Carcinoma According to Mayo Criteria.
Lu W; Chen X; Ni J; Li Z; Su T; Li S; Wan X
Front Oncol; 2022; 12():895834. PubMed ID: 35795035
[TBL] [Abstract][Full Text] [Related]
20. A Nomogram Model for Predicting Recurrence of Stage I-III Endometrial Cancer Based on Inflammation-Immunity-Nutrition Score (IINS) and Traditional Classical Predictors.
Jiang P; Wang J; Gong C; Yi Q; Zhu M; Hu Z
J Inflamm Res; 2022; 15():3021-3037. PubMed ID: 35645577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
